A Case of Bone, Lung, Pleural and Liver Metastases from Renal Cell Carcinoma Which Responded Remarkably Well to Zoledronic Acid Monotherapy

• Published in: Japanese journal of clinical oncology Vol. 39; no. 11; pp. 745 - 750
• Main Authors: Miwa, Sotaro, Mizokami, Atsushi, Konaka, Hiroyuki, Izumi, Kouji, Nohara, Takahiro, Namiki, Mikio
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.11.2009
• Subjects: Adult; Antineoplastic Agents - therapeutic use; Bone Density Conservation Agents - therapeutic use; bone metastasis; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Carcinoma, Renal Cell - secondary; Diphosphonates - therapeutic use; Humans; Imidazoles - therapeutic use; Kidney Neoplasms - pathology; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; lung metastasis; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Male; pleural metastasis; Pleural Neoplasms - drug therapy; Pleural Neoplasms - secondary; renal cell carcinoma; Tomography, X-Ray Computed; Treatment Outcome; zoledronic acid; pleural metastasis; renal cell carcinoma; lung metastasis; bone metastasis; zoledronic acid
• ISSN: 0368-2811; 1465-3621
• DOI: 10.1093/jjco/hyp122

Herein, we report a rare case in which bisphosphonate zoledronic acid (ZA) effectively treated not only multiple bone metastases but also lung, pleural and liver metastases from renal cell carcinoma (RCC). Recently, ZA is used to treat skeletal-related events (SREs) such as bone pain caused by bone metastasis from many kinds of cancer. The patient in the present report had multiple bone metastases from RCC. Remarkable improvement of the bone metastasis was observed following treatment with ZA at a dosage of 4 mg administered once every 4 weeks. Moreover, lung, pleural and liver metastases also diminished markedly in size in response to the treatment. The metastases have shown no progression for 20 months since starting the ZA treatment. We believe that the present report is the first of its kind announcing that ZA monotherapy has been effective for lung, pleural and liver metastases from RCC.